Mainz Biomed BV (MYNZ)vsWaters Corporation (WAT)
MYNZ
Mainz Biomed BV
$0.50
+0.16%
HEALTHCARE · Cap: $7.90M
WAT
Waters Corporation
$302.32
+0.13%
HEALTHCARE · Cap: $29.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 479532% more annual revenue ($3.17B vs $659,940). WAT leads profitability with a 20.3% profit margin vs 0.0%. WAT earns a higher WallStSmart Score of 60/100 (C).
MYNZ
Avoid18
out of 100
Grade: F
WAT
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MYNZ.
Margin of Safety
-349.9%
Fair Value
$73.17
Current Price
$302.32
$229.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 33.8%
Safe zone — low bankruptcy risk
Every $100 of equity generates 29 in profit
Keeps 20 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Moderate valuation
Earnings declined 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : MYNZ
The strongest argument for MYNZ centers on Price/Book.
Bull Case : WAT
The strongest argument for WAT centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 20.3% and operating margin at 33.8%. PEG of 1.25 suggests the stock is reasonably priced for its growth.
Bear Case : MYNZ
The primary concerns for MYNZ are EPS Growth, Market Cap, Profit Margin.
Bear Case : WAT
The primary concerns for WAT are P/E Ratio, EPS Growth.
Key Dynamics to Monitor
MYNZ profiles as a value stock while WAT is a mature play — different risk/reward profiles.
WAT carries more volatility with a beta of 1.20 — expect wider price swings.
WAT is growing revenue faster at 6.8% — sustainability is the question.
WAT generates stronger free cash flow (126M), providing more financial flexibility.
Bottom Line
WAT scores higher overall (60/100 vs 18/100), backed by strong 20.3% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mainz Biomed BV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Mainz Biomed BV is an innovative biotechnology company specializing in the development of advanced diagnostic solutions for early cancer detection, with a particular emphasis on gastrointestinal disorders. The company's flagship product, a proprietary non-invasive colorectal cancer screening test, employs state-of-the-art biomarker technology to improve the accuracy and accessibility of screenings. As a key player in the rapidly expanding diagnostics market, Mainz Biomed is dedicated to meeting critical clinical needs and enhancing patient outcomes. With a strong intellectual property position and a focus on research and development, the company is poised to capitalize on the increasing global demand for effective cancer diagnostic tools.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?